

Ivan Koychev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/867822/publications.pdf>

Version: 2024-02-01

47
papers

1,592
citations

394421

19
h-index

330143

37
g-index

57
all docs

57
docs citations

57
times ranked

2584
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model. <i>BMC Medicine</i> , 2022, 20, 45.	5.5	9
2	Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. <i>Brain Communications</i> , 2022, 4, fcab297.	3.3	147
3	Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study. <i>British Journal of Psychiatry</i> , 2021, 218, 261-267.	2.8	12
4	Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 177-195.	2.6	25
5	Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. <i>EClinicalMedicine</i> , 2021, 31, 100683.	7.1	435
6	Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 89.	6.2	28
7	Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, jnnp-2021-326405.	1.9	80
8	An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study. <i>Trials</i> , 2021, 22, 508.	1.6	20
9	Secondary Prevention of Dementia: Combining Risk Factors and Scalable Screening Technology. <i>Frontiers in Neurology</i> , 2021, 12, 772836.	2.4	9
10	Prediction of Alzheimer's disease biomarker status defined by the ATN framework among cognitively healthy individuals: results from the EPAD longitudinal cohort study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 143.	6.2	19
11	Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1413-1418.	5.0	17
12	Impact of APOE4 and future family history on early adulthood cardiovascular risk: Results from a 30-year cohort study. <i>Alzheimer's and Dementia</i> , 2020, 16, e040454.	0.8	0
13	Prediction of rapid amyloid and phosphorylated tau accumulation in cognitively healthy individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12019.	2.4	10
14	Gallery Game: Smartphone-based assessment of long-term memory in adults at risk of Alzheimer's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2020, 42, 329-343.	1.3	19
15	The Dementias Platform UK (DPUK) Data Portal. <i>European Journal of Epidemiology</i> , 2020, 35, 601-611.	5.7	45
16	Evaluating the Feasibility of Frequent Cognitive Assessment Using the Mezurio Smartphone App: Observational and Interview Study in Adults With Elevated Dementia Risk. <i>JMIR MHealth and UHealth</i> , 2020, 8, e16142.	3.7	33
17	Evaluation of [13N]ammonia positron emission tomography as a potential method for quantifying glutamine synthetase activity in the human brain. <i>EJNMMI Research</i> , 2020, 10, 146.	2.5	1
18	Dementias Platform UK Clinical Studies and Great Minds Register: protocol of a targeted brain health studies recontact database. <i>BMJ Open</i> , 2020, 10, e040766.	1.9	2

#	ARTICLE	IF	CITATIONS
19	Dementias Platform UK Clinical Studies and Great Minds Register: protocol of a targeted brain health studies recontact database. <i>BMJ Open</i> , 2020, 10, e040766.	1.9	6
20	Implementing a digital clinical decision support tool for side effects of antipsychotics: a focus group study. <i>Evidence-Based Mental Health</i> , 2019, 22, 56-60.	4.5	16
21	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. <i>BMJ Open</i> , 2019, 9, e024498.	1.9	18
22	31â€...Prediction of emerging amyloid and tau pathology in cognitively healthy individuals: a longitudinal CSF study. , 2019, , .		0
23	Digital technologies for the assessment of cognition: a clinical review. <i>Evidence-Based Mental Health</i> , 2018, 21, 67-71.	4.5	31
24	Gait in Mild Alzheimer's Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 331-341.	2.6	42
25	Imaging A β and tau in early stage Alzheimer's disease with [18F]AV45 and [18F]AV1451. <i>EJNMMI Research</i> , 2018, 8, 19.	2.5	14
26	A β ₄₂ /A β ₄₀ and A β ₄₂ /A β ₃₈ Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer's Disease: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1377-1383.	2.6	23
27	Reply to: Letter to the Editor: Sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained?. <i>Psychological Medicine</i> , 2017, 47, 983-983.	4.5	0
28	Cognitive-behavioural therapy for non-motor symptoms of Parkinson's disease: a clinical review. <i>Evidence-Based Mental Health</i> , 2017, 20, 15-20.	4.5	72
29	Effects of Acute Ketamine Infusion on Visual Working Memory: Event-Related Potentials. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017, 2, 253-262.	1.5	8
30	PET Tau and Amyloid- β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 283-293.	2.6	67
31	The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. <i>Psychological Medicine</i> , 2016, 46, 3443-3450.	4.5	25
32	Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies. <i>Translational Psychiatry</i> , 2016, 6, e811-e811.	4.8	15
33	Sudden-Onset Catatonia Following Clozapine Withdrawal. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e899-e899.	2.2	10
34	Neurobiological basis of motivational deficits in psychopathology. <i>European Neuropsychopharmacology</i> , 2015, 25, 1225-1238.	0.7	68
35	The effect of penicillin therapy on cognitive outcomes in neurosyphilis: a systematic review of the literature. <i>General Hospital Psychiatry</i> , 2015, 37, 49-52.	2.4	13
36	P.3.b.007 Altered dorsolateral prefrontal cortex glutamate and striatal dopamine relationship in subjects at ultra high risk of psychosis. <i>European Neuropsychopharmacology</i> , 2014, 24, S494-S495.	0.7	0

#	ARTICLE	IF	CITATIONS
37	Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. <i>Psychopharmacology</i> , 2013, 227, 331-345.	3.1	34
38	Differential effect of amisulpride on cognition in schizotypy: validation of models for the early identification of cognitive enhancing agents. <i>Lancet, The</i> , 2013, 381, S59.	13.7	2
39	The effects of ketamine and risperidone on eye movement control in healthy volunteers. <i>Translational Psychiatry</i> , 2013, 3, e334-e334.	4.8	21
40	A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A three-center double-blind placebo-controlled study. <i>European Neuropsychopharmacology</i> , 2012, 22, 469-481.	0.7	40
41	Core dysfunction in schizophrenia: electrophysiology trait biomarkers. <i>Acta Psychiatrica Scandinavica</i> , 2012, 126, 59-71.	4.5	17
42	Abnormal neural oscillations in schizotypy during a visual working memory task: Support for a deficient top-down network?. <i>Neuropsychologia</i> , 2011, 49, 2866-2873.	1.6	22
43	Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia. <i>Journal of Psychopharmacology</i> , 2011, 25, 1207-1225.	4.0	22
44	New visual information processing abnormality biomarkers for the diagnosis of schizophrenia. <i>Expert Opinion on Medical Diagnostics</i> , 2011, 5, 357-368.	1.6	14
45	Visual information processing deficits as biomarkers of vulnerability to schizophrenia: An event-related potential study in schizotypy. <i>Neuropsychologia</i> , 2010, 48, 2205-2214.	1.6	54
46	S.27.01 From animals to man: overview and main findings from the NewMood project. <i>European Neuropsychopharmacology</i> , 2009, 19, S214.	0.7	1
47	Brexipiprazole versus placebo or other antidepressive agents for treating depression. <i>The Cochrane Library</i> , 0, , .	2.8	2